Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
HOME > COLUMN
COLUMN
- The Power in Teaching Your Team “How to Speak”
May 28, 2019
- Unlock Hidden Talent by Hiring for These Four Traits
May 10, 2019
- No Drug “Reviews” for 1st Time in 2 Years
April 22, 2019
- 6 Core Elements of Recruitment Mastery
March 22, 2019
- Is Japan’s Cost-Effectiveness Assessment Scheme Cost Effective?
February 27, 2019
- Why Top-Tier Recruiters Must Embrace Their Creative Side
January 31, 2019
- Expat Truths from the Japanese Medical Device World
December 3, 2018
- Why Did the Project Take so Long?
November 16, 2018
- Finding Captains in Your Organization
October 12, 2018
- Riding the Trend: Staffing Pharma Startups in Japan
September 7, 2018
- How Having a Great CSR Program Can Help with Recruiting and Retaining Top Talent
August 16, 2018
- Rare Disease Pharmaceuticals in Japan to See New Demand for Skilled Human Resources
July 20, 2018
- 5 Billion Yen Blockbuster?
June 20, 2018
- It Is Thumbs Up for Cell Therapy in Japan
March 23, 2018
- Unique Opportunities at Pharmaceutical Companies Treating Rare Diseases
February 23, 2018
- When Leading Teams, Focus on the Principles, Not the Personalities
January 26, 2018
- What to Do about the Feeling of Torschlusspanik?
October 27, 2017
- Women! Rock the Boat and Get Promoted
September 22, 2017
- Getting the Right Message
August 25, 2017
- Putting on Your Pants
July 21, 2017
ページ
The female manager ratio at foreign drug makers in Japan has been on the steady rise since the enforcement in April 2016 of the Act on Promotion of Women’s Participation and Career Advancement in the Workplace. Women now account for…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Earlier this year, I attended a conference discussing the trends of Japan’s pharmaceutical industry. The objective of the conference was to determine what Japanese pharmaceutical companies were doing, and what they could be doing, to make themselves more competitive on…